On June 18th, Glory Hui reported that Merck & Co. announced that the US Food and Drug Administration (FDA) has approved its next-generation Capvaxive vaccine for the prevention of pneumococcal disease in adults aged 18 and over. The pharmaceutical company stated that the wholesale purchase price of the vaccine is $ 287 per dose, but most people may not need to pay for the vaccine if it is recommended by the Centers for Disease Control and Prevention (CDC). The company expects the vaccine to be launched at the end of the summer based on the advice of the CDC's advisors, who are expected to discuss the vaccine at a meeting later this month.